Fertility and Sterility
Volume 91, Issue 3 , Pages 705-714 , March 2009

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count

  • Simone L. Broer, B.Sc.

      Affiliations

    • Department of Reproductive Medicine, Division of Obstetrics, Neonatology, and Gynecology, University Medical Center, Utrecht, The Netherlands
    • ,
  • Ben Willem J. Mol, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Dave Hendriks, M.D., Ph.D.

      Affiliations

    • Department of Reproductive Medicine, Division of Obstetrics, Neonatology, and Gynecology, University Medical Center, Utrecht, The Netherlands
    • ,
  • Frank J.M. Broekmans, M.D., Ph.D.

      Affiliations

    • Department of Reproductive Medicine, Division of Obstetrics, Neonatology, and Gynecology, University Medical Center, Utrecht, The Netherlands
    • Corresponding Author InformationReprint requests: F. Broekmans, M.D., Department of Reproductive Medicine, Division of Obstetrics, Neonatology, and Gynecology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands (FAX: 31-30-2505433).

Received 19 July 2007 ,Revised 5 December 2007 ,Accepted 5 December 2007.

References 

  1. Leridon H. Demographic effects of the introduction of steroid contraception in developed countries. Hum Reprod Update. 2006;12:603–616
  2. Spira A. The decline of fecundity with age. Am J.Human Biol. 1988;(Suppl 1):15–22
  3. Wood JW. Fecundity and natural fertility in humans. Oxf Rev Reprod Biol. 1989;11:61–109
  4. te Velde ER, Pearson PL. The variability of female reproductive aging. Hum Reprod Update. 2002;8:141–154
  5. Gougeon A, Echochard R, Thalabard JC. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of nongrowing and early- growing follicles in aging women. Biol Reprod. 1994;50:653–663
  6. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685–718
  7. Klinkert ER, Broekmans FJ, Looman CW, te Velde ER. A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cycles. Fertil Steril. 2004;81:1247–1253
  8. Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril. 2007;87:764–775
  9. de Koning CH, Benjamins T, Harms P, Homburg R, van Montfrans JM, Gromoll J, et al. The distribution of FSH receptor isoforms is related to basal FSH levels in subfertile women with normal menstrual cycles. Hum Reprod. 2006;21:443–446
  10. Lashen H, Ledger W, Lopez-Bernal A, Barlow D. Poor responders to ovulation induction: is proceeding to in-vitro fertilization worthwhile?. Hum Reprod. 1999;14:964–969
  11. van Disseldorp J, Eijkemans MJ, Klinkert ER, te Velde ER, Fauser BC, Broekmans FJ. Cumulative live birth rates following IVF in 41- to 43-year-old women presenting with favourable ovarian reserve characteristics. Reprod Biomed Online. 2007;14:455–463
  12. Hendriks DJ, Mol BW, Bancsi LF, te Velde ER, Broekmans FJ. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril. 2005;83:291–301
  13. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996;81:571–576
  14. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83
  15. Fanchin R, Schonauer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum antimullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod. 2003;18:328–332
  16. La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, et al. Anti-mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod. 2004;19:2738–2741
  17. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB, et al. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J.Clin Endocrinol Metab. 1990;70:16–22
  18. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77:357–362
  19. Gruijters MJ, Visser JA, Durlinger AL, Themmen AP. Anti-mullerian hormone and its role in ovarian function. Mol Cell Endocrinol. 2003;211:85–90
  20. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, Jong FH, et al. Serum antimullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–3071
  21. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, te Velde ER, Broekmans FJ. Anti-mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J.Clin Endocrinol Metab. 2006;91:4057–4063
  22. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum antimullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21:3103–3107
  23. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77:468–471
  24. van Rooij IA, de Jong E, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment. Fertil Steril. 2004;81:1478–1485
  25. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323–1329
  26. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making. 1993;13:313–321
  27. Midgette AS, Stukel TA, Littenberg B. A meta-analytic method for summarizing diagnostic test performances: receiver-operating-characteristic-summary point estimates. Med Decis Making. 1993;13:253–257
  28. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–1316
  29. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, antimullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?. BJOG. 2005;112:1384–1390
  30. Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M. Inhibin B and antimullerian hormone: markers of ovarian response in IVF/ICSI patients?. BJOG. 2004;111:1248–1253
  31. Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 antimullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist—gonadotropin treatment. Hum Reprod. 2005;20:915–922
  32. Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol. 2005;45:20–24
  33. Eldar-Geva T, Ben Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, antimullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod. 2005;20:3178–3183
  34. McIlveen M, Skull JD, Ledger WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod. 2007;22:778–785
  35. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril. 2006;85:592–596
  36. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007;22:766–771
  37. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of antimullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21:2022–2026
  38. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril. 2007;87:223–226
  39. Freour T, Mirallie S, Bach-Ngohou K, Denis M, Barriere P, Masson D. Measurement of serum antimullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta. 2007;375:162–164
  40. Kwee J, Schats R, McDonnell J, Themmen AP, de Jong FH, Lambalk CB. Evaluation of AMH as test for the prediction of ovarian reserve. Fertil Steril. Published online October 17, 2007. [E-pub ahead of print.]
  41. Cook CL, Siow Y, Taylor S, Fallat ME. Serum mullerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril. 2000;73:859–861
  42. Hansen KR, Morris JL, Thyer AC, Soules MR. Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting. Fertil Steril. 2003;80:577–583
  43. Scheffer GJ, Broekmans FJ, Bancsi LF, Habbema JD, Looman CW, te Velde ER. Quantitative transvaginal two- and three-dimensional sonography of the ovaries: reproducibility of antral follicle counts. Ultrasound Obstet Gynecol. 2002;20:270–275
  44. Pache TD, Wladimiroff JW, de Jong FH, Hop WC, Fauser BCJM. Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. Fertil Steril. 1990;54:638–642
  45. Kwee J, Elting MW, Schats R, Bezemer PD, Lambalk CB, Schoemaker J. Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. Hum Reprod. 2003;18:1422–1427
  46. Boomsma CM, Macklon NS. What can the clinician do to improve implantation?. Reprod Biomed Online. 2006;13:845–855
  47. Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet. 1996;348:1402–1406
  48. van der Gaast MH, Eijkemans MJ, van der Net JB, de Boer EJ, Burger CW, van Leeuwen FE, et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online. 2006;13:476–480
  49. Mol BW, Verhagen TE, Hendriks DJ, Collins JA, Coomarasamy A, Opmeer BC, et al. Value of ovarian reserve testing before IVF: a clinical decision analysis. Hum Reprod. 2006;21:1816–1823
  50. Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a “standard” dose of 150 IU/day in “standard” patients undergoing IVF/ICSI treatment. Hum Reprod. 2003;18:2275–2282
  51. Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod. 2005;20:611–615
  52. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update. 2003;9:61–76
  53. de Koning CH, Popp-Snijders C, Martens F, Lambalk CB. Falsely elevated follicle-stimulating hormone levels in women with regular menstrual cycles due to interference in immunoradiometric assay. J.Assist Reprod Genet. 2000;17:457–459
  54. Lambalk CB, de Koning CH. Interpretation of elevated FSH in the regular menstrual cycle. Am J Human Biol. 1998;30:215–220
  55. Hendriks D, te Velde ER, Looman CW, Bancsi LF, Broekmans FJ. The role of poor response in the prediction of the cumulative ongoing pregnancy rate in in vitro fertilisation. In: Dynamic and basal ovarian reserve tests for outcome prediction in IVF: comparisons and meta-analyses. [Academic thesis, University Utrecht]. 2005:162–179.
  56. Broekmans FJ, Knauff EA, te Velde ER, Macklon NS, Fauser BC. Female reproductive ageing: current knowledge and future trends. Trends Endocrinol Metab. 2007;18:58–65
  57. Hefler LA, Grimm C, Bentz EK, Reinthaller A, Heinze G, Tempfer CB. A model for predicting age at menopause in white women. Fertil Steril. 2006;85:451–454

 S.L.B. has nothing to disclose. B.W.J.M. has nothing to disclose. D.H. has nothing to disclose. F.J.M.B. has nothing to disclose.

PII: S0015-0282(07)04195-7

doi: 10.1016/j.fertnstert.2007.12.013

Fertility and Sterility
Volume 91, Issue 3 , Pages 705-714 , March 2009

Article Tools

* Image Usage & Resolution